Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks. (Supported by Eli Lilly; ACHIEVE-1 ClinicalTrials.gov number, NCT05971940.).
Authors
- Wen‐Shuo Wu (ORCID: https://orcid.org/0000-0002-6259-3409)
- David A. Cox (ORCID: https://orcid.org/0000-0003-2052-9836)
- Max Denning (ORCID: https://orcid.org/0000-0001-6215-6885)
- Stanley H. Hsia (ORCID: https://orcid.org/0000-0003-0945-321X)
- Lisa Ludwig (ORCID: https://orcid.org/0000-0002-2838-9754)
- Julio Rosenstock (ORCID: https://orcid.org/0000-0001-8324-3275)
- Jianghao Li (ORCID: https://orcid.org/0000-0002-6807-9128)
- Laura Fernández Landó (ORCID: https://orcid.org/0000-0002-0969-6214)
- Yanyun Chen (ORCID: https://orcid.org/0009-0007-6327-7997)
- Sarah Eyde
- Rong Liu (ORCID: https://orcid.org/0000-0003-2561-348X)
- Luis Nevárez Ruiz
Institutions
- Autonomous University of Chihuahua (MX)
- Eli Lilly (United States) (US)
- Velocity Clinical Research (United States) (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1056/nejmoa2505669
- Citations
- 55
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 71.22